CA3228178A1 - Anti-glyco-muc4 antibodies and their uses - Google Patents
Anti-glyco-muc4 antibodies and their uses Download PDFInfo
- Publication number
- CA3228178A1 CA3228178A1 CA3228178A CA3228178A CA3228178A1 CA 3228178 A1 CA3228178 A1 CA 3228178A1 CA 3228178 A CA3228178 A CA 3228178A CA 3228178 A CA3228178 A CA 3228178A CA 3228178 A1 CA3228178 A1 CA 3228178A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- antibody
- muc4
- cdr
- glyco
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4256—Tumor associated carbohydrates
- A61K40/4257—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163229839P | 2021-08-05 | 2021-08-05 | |
| US63/229,839 | 2021-08-05 | ||
| US202163241837P | 2021-09-08 | 2021-09-08 | |
| US63/241,837 | 2021-09-08 | ||
| US202163270642P | 2021-10-22 | 2021-10-22 | |
| US63/270,642 | 2021-10-22 | ||
| PCT/US2022/039390 WO2023014863A1 (en) | 2021-08-05 | 2022-08-04 | Anti-glyco-muc4 antibodies and their uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3228178A1 true CA3228178A1 (en) | 2023-02-09 |
Family
ID=83189120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3228178A Pending CA3228178A1 (en) | 2021-08-05 | 2022-08-04 | Anti-glyco-muc4 antibodies and their uses |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250101126A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4380604A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024531915A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240107093A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022324456A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3228178A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202325726A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023014863A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202448960A (zh) * | 2023-02-07 | 2024-12-16 | 美商Go治療公司 | 包括抗醣MUC4抗體及MIC蛋白α1-α2結構域之抗體融合蛋白及其用途 |
Family Cites Families (163)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR104E (cg-RX-API-DMAC7.html) | ||||
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5006459A (en) | 1986-03-31 | 1991-04-09 | T Cell Sciences, Inc. | Therapeutic and diagnostic methods using soluble T cell surface molecules |
| WO1989012624A2 (en) | 1988-06-14 | 1989-12-28 | Cetus Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5993434A (en) | 1993-04-01 | 1999-11-30 | Genetronics, Inc. | Method of treatment using electroporation mediated delivery of drugs and genes |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
| JP3876002B2 (ja) | 1997-04-14 | 2007-01-31 | ミクロメート・アクチエンゲゼルシャフト | 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用 |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US6055453A (en) | 1997-08-01 | 2000-04-25 | Genetronics, Inc. | Apparatus for addressing needle array electrodes for electroporation therapy |
| US6241701B1 (en) | 1997-08-01 | 2001-06-05 | Genetronics, Inc. | Apparatus for electroporation mediated delivery of drugs and genes |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| US6678556B1 (en) | 1998-07-13 | 2004-01-13 | Genetronics, Inc. | Electrical field therapy with reduced histopathological change in muscle |
| AU1728800A (en) | 1998-11-18 | 2000-06-05 | Genentech Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
| US7171264B1 (en) | 1999-05-10 | 2007-01-30 | Genetronics, Inc. | Intradermal delivery of active agents by needle-free injection and electroporation |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| HK1052372A1 (zh) | 2000-02-24 | 2003-09-11 | Xcyte Therapies, Inc. | 细胞的同步刺激和富集 |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| WO2001066149A2 (en) | 2000-03-03 | 2001-09-13 | Valentis, Inc. | Nucleic acid formulations for gene delivery and methods of use |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
| US20040014645A1 (en) | 2002-05-28 | 2004-01-22 | Advisys, Inc. | Increased delivery of a nucleic acid construct in vivo by the poly-L-glutamate ("PLG") system |
| US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
| US20050070841A1 (en) | 2002-07-04 | 2005-03-31 | Inovio As | Electroporation device and injection apparatus |
| ES2369542T3 (es) | 2002-07-31 | 2011-12-01 | Seattle Genetics, Inc. | Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa. |
| US20050271615A1 (en) | 2002-08-30 | 2005-12-08 | Doron Shabat | Self-immolative dendrimers releasing many active moieties upon a single activating event |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US7105657B2 (en) * | 2002-11-08 | 2006-09-12 | Board Of Regents Of The University Of Nebraska | Compositions and methods for inhibiting pancreatic cancer metastasis |
| WO2004043493A1 (en) | 2002-11-14 | 2004-05-27 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
| AU2003295471B2 (en) | 2002-11-15 | 2011-08-25 | Genmab A/S | Human monoclonal antibodies against CD25 |
| KR101498588B1 (ko) | 2003-01-22 | 2015-03-05 | 로슈 글리카트 아게 | 융합 구성체와 Fc 수용체 결합 친화도 및 이펙터 기능이 증가된 항체를 생성하기 위한 이의 용도 |
| US7662387B2 (en) | 2003-02-20 | 2010-02-16 | Seattle Genetics | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| CA2556752C (en) | 2004-02-23 | 2016-02-02 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| AU2005250408B2 (en) | 2004-05-27 | 2010-09-23 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
| TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| FR2879605B1 (fr) | 2004-12-16 | 2008-10-17 | Centre Nat Rech Scient Cnrse | Production de formats d'anticorps et applications immunologiques de ces formats |
| JP5838021B2 (ja) | 2005-04-15 | 2015-12-24 | マクロジェニクス,インコーポレーテッド | 共有結合型ダイアボディとその使用 |
| HUE035853T2 (en) | 2005-07-18 | 2018-05-28 | Seattle Genetics Inc | Beta-glucuronide-linker-drug conjugates |
| CN101370927A (zh) | 2005-12-07 | 2009-02-18 | 基因特伦尼克斯公司 | 可变容积电穿孔室以及其方法 |
| MX2008009956A (es) | 2006-02-02 | 2008-12-12 | Syntarga Bv | Analogos de cc-1065 solubles en agua y sus conjugados. |
| PL2099823T5 (pl) | 2006-12-01 | 2023-02-20 | Seagen Inc. | Wariant środków wiążących cel i jego zastosowania |
| WO2009077483A1 (en) | 2007-12-14 | 2009-06-25 | Novo Nordisk A/S | Antibodies against human nkg2d and uses thereof |
| WO2008119567A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
| EP2158221B1 (en) | 2007-06-21 | 2018-08-29 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| BRPI0820229A2 (pt) | 2007-11-28 | 2017-05-09 | A Stevenson Cheri | conjugados de análogos de fumagilina biodegradáveis biocompatíveis |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US9273136B2 (en) | 2008-08-04 | 2016-03-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fully human anti-human NKG2D monoclonal antibodies |
| US20100152725A1 (en) | 2008-12-12 | 2010-06-17 | Angiodynamics, Inc. | Method and system for tissue treatment utilizing irreversible electroporation and thermal track coagulation |
| JP5734201B2 (ja) | 2008-12-19 | 2015-06-17 | マクロジェニクス,インコーポレーテッド | 共有結合型ダイアボディ及びその使用 |
| JP2012528240A (ja) | 2009-05-28 | 2012-11-12 | メルサナ セラピューティックス, インコーポレイテッド | 可変速度放出リンカーを含むポリアル−薬物コンジュゲート |
| US9588121B2 (en) * | 2009-11-06 | 2017-03-07 | Go Therapeutics, Inc. | Method for early detection of cancer |
| EP2511718B1 (en) | 2009-12-07 | 2017-07-05 | Ntt Docomo, Inc. | Propagation path estimation method, program, and device |
| US20150165065A1 (en) | 2009-12-31 | 2015-06-18 | Avidbiotics Corp. | Non-natural mic proteins |
| US8658765B2 (en) | 2009-12-31 | 2014-02-25 | Avidbiotics Corp. | Non-natural MIC proteins |
| US8796420B2 (en) | 2009-12-31 | 2014-08-05 | Avidbiotics Corp. | Non-natural MIC proteins |
| US8785604B2 (en) | 2010-02-18 | 2014-07-22 | Effimune | Anti-CD28 humanized antibodies |
| US8349308B2 (en) | 2010-03-26 | 2013-01-08 | Mersana Therapeutics, Inc. | Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| LT2691417T (lt) | 2011-03-29 | 2018-10-25 | Roche Glycart Ag | Antikūno fc variantai |
| DK2707031T3 (da) | 2011-05-08 | 2019-10-07 | Legochem Biosciences Inc | Protein-active agent conjugates and method for preparing the same |
| WO2012170470A1 (en) * | 2011-06-06 | 2012-12-13 | Board Of Regents Of The University Of Nebraska | Compositions and methods for detection and treatment of cancer |
| LT2748201T (lt) | 2011-08-23 | 2018-02-26 | Roche Glycart Ag | Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė |
| BR112014013526A8 (pt) | 2011-12-05 | 2017-06-13 | Igenica Biotherapeutics Inc | conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados |
| WO2013096901A1 (en) | 2011-12-23 | 2013-06-27 | Mersana Therapeutics, Inc. | Pharmaceutical formulations for fumagillin derivative-phf conjugates |
| BR112014020502A2 (pt) | 2012-02-22 | 2019-09-24 | Univ Pennsylvania | sequência de ácido nucleico isolada, receptor quimérico de antígeno isolado, célula, vetor, e, métodos para estimular uma resposta imune, para fornecer uma imunidade antitumoral, para tratamento de um mamífero, para gerar e para expandir uma população de células - t, e para modular a quantidade de citocina secretada por uma célula -t |
| US9504756B2 (en) | 2012-05-15 | 2016-11-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
| WO2014008375A1 (en) | 2012-07-05 | 2014-01-09 | Mersana Therapeutics, Inc. | Terminally modified polymers and conjugates thereof |
| US20150191543A1 (en) | 2012-08-06 | 2015-07-09 | The Regents Of The University Of California | Engineered antibody fragments for targeting and imaging cd8 expression in vivo |
| WO2014093394A1 (en) | 2012-12-10 | 2014-06-19 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| US10226535B2 (en) | 2012-12-10 | 2019-03-12 | Mersana Therapeutics, Inc. | Auristatin compounds and conjugates thereof |
| US9872918B2 (en) | 2012-12-12 | 2018-01-23 | Mersana Therapeutics, Inc. | Hydroxyl-polymer-drug-protein conjugates |
| AU2014233478A1 (en) | 2013-03-15 | 2015-09-24 | Abbvie Biotechnology Ltd. | Anti-CD25 antibodies and their uses |
| JP2016538877A (ja) | 2013-10-14 | 2016-12-15 | シンアフィックス ビー.ブイ. | 修飾糖タンパク質、タンパク質コンジュゲート及びそれらの調製方法 |
| WO2015057064A1 (en) | 2013-10-14 | 2015-04-23 | Synaffix B.V. | Modified glycoprotein, protein-conjugate and process for the preparation thereof |
| WO2015057066A1 (en) | 2013-10-14 | 2015-04-23 | Synaffix B.V. | Glycoengineered antibody, antibody-conjugate and methods for their preparation |
| WO2015057065A1 (en) | 2013-10-14 | 2015-04-23 | Synaffix B.V. | Glycoengineered antibody, antibody-conjugate and methods for their preparation |
| EP3097200A1 (en) | 2014-01-24 | 2016-11-30 | SynAffix B.V. | Process for the attachment of a galnac moiety comprising a (hetero)aryl group to a glcnac moiety, and product obtained thereby |
| WO2015119180A1 (ja) * | 2014-02-06 | 2015-08-13 | 医化学創薬株式会社 | ムチン4(muc4)糖ペプチドに対する抗体及びその用途 |
| KR101628872B1 (ko) | 2014-05-28 | 2016-06-09 | 주식회사 레고켐 바이오사이언스 | 자가-희생 기를 포함하는 화합물 |
| EP3177633B1 (en) | 2014-08-04 | 2022-07-20 | SynAffix B.V. | Process for the modification of a glycoprotein using a beta-(1,4)-n-acetylgalactosaminyltransferase or a mutant thereof |
| PL3177643T3 (pl) | 2014-08-04 | 2019-09-30 | F.Hoffmann-La Roche Ag | Dwuswoiste cząsteczki wiążące antygen aktywujące komórki T |
| EP3733209A1 (en) | 2014-10-03 | 2020-11-04 | Synaffix B.V. | Sulfamide linker, conjugates thereof, and methods of preparation |
| US11117969B2 (en) | 2014-12-05 | 2021-09-14 | Xyphos Biosciences Inc. | Insertable variable fragments of antibodies and modified α1-α2 domains of NKG2D ligands |
| LT3227311T (lt) | 2014-12-05 | 2022-02-25 | Xyphos Biosciences Inc. | Įterpiami variabilūs antikūnų fragmentai ir nkg2d ligandų modifikuoti a1-a2 domenai |
| CN107810273B (zh) | 2015-04-23 | 2022-09-27 | 西纳福克斯股份有限公司 | 用为或衍生自β-(1,4)-N-乙酰半乳糖胺转移酶的糖基转移酶修饰糖蛋白的方法 |
| PE20180188A1 (es) | 2015-05-08 | 2018-01-23 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales |
| EP3770168A1 (en) | 2015-05-18 | 2021-01-27 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| HUE067376T2 (hu) | 2015-08-04 | 2024-10-28 | Xyphos Biosciences Inc | Antitestek beilleszthetõ változó fragmentumai és NKG2D ligandumok módosított a1-a2 doménjei, valamint nem természetes NKG2D receptorokat megkötõ nem természetes NKG2D ligandumok |
| WO2017051254A1 (en) | 2015-09-25 | 2017-03-30 | Legochem Biosciences, Inc. | Compositions and methods related to anti-egfr antibody drug conjugates |
| WO2017051249A1 (en) | 2015-09-25 | 2017-03-30 | Legochem Biosciences, Inc. | Compositions and methods related to anti-cd19 antibody drug conjugates |
| MX2018004721A (es) | 2015-10-23 | 2018-07-06 | Eureka Therapeutics Inc | Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas. |
| HUE067016T2 (hu) | 2015-11-25 | 2024-09-28 | Ligachem Biosciences Inc | Önfeláldozó csoportokat tartalmazó konjugátumok és ezekkel kapcsolos eljárások |
| JP7120765B2 (ja) | 2015-11-25 | 2022-08-17 | レゴケム バイオサイエンシズ, インク. | ペプチド基を含む複合体及びそれに関連する方法 |
| CN107847605B (zh) | 2015-11-25 | 2021-12-24 | 乐高化学生物科学股份有限公司 | 包含分支接头的抗体-药物缀合物及其相关方法 |
| DK3390450T3 (da) | 2015-12-15 | 2021-03-01 | Ose Immunotherapeutics | Anti-cd28-humaniserede antistoffer formuleret til indgivelse til mennesker |
| WO2017137457A1 (en) | 2016-02-08 | 2017-08-17 | Synaffix B.V. | Antibody-conjugates with improved therapeutic index for targeting cd30 tumours and method for improving therapeutic index of antibody-conjugates |
| WO2017137456A1 (en) | 2016-02-08 | 2017-08-17 | Synaffix B.V. | Bioconjugates containing sulfamide linkers for use in treatment |
| US10874746B2 (en) | 2016-02-08 | 2020-12-29 | Synaffix B.V. | Sulfamide linkers for use in bioconjugates |
| EP3475300A2 (en) | 2016-06-24 | 2019-05-01 | Xyphos Biosciences Inc. | Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands |
| BR112019012937A2 (pt) | 2016-12-23 | 2019-12-10 | Heidelberg Pharma Research Gmbh | novo conjugado de amanitina |
| WO2018182341A1 (ko) | 2017-03-29 | 2018-10-04 | 주식회사 레고켐 바이오사이언스 | 피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물 |
| CN110997013B (zh) | 2017-07-24 | 2022-09-20 | 瑞泽恩制药公司 | 抗cd8抗体和其用途 |
| MA52206A (fr) | 2018-03-27 | 2021-02-17 | Xyphos Biosciences Inc | Domaines a1-a2 modifiés de ligands nkg2d non naturels se liant à des récepteurs nkg2d non naturels |
| EP3773740A1 (en) | 2018-04-13 | 2021-02-17 | Heidelberg Pharma Research GmbH | Targeted amatoxin conjugate for the treatment of solid tumors |
| CN110818802B (zh) | 2018-08-08 | 2022-02-08 | 华夏英泰(北京)生物技术有限公司 | 一种嵌合t细胞受体star及其应用 |
| US20200147175A1 (en) * | 2018-11-10 | 2020-05-14 | Consejo Nacional De Investigaciones Científicas Y Técnicas | Method for treating anti-her2 therapy-resistant muc4+ her2+ cancer |
| US20220096641A1 (en) | 2019-01-03 | 2022-03-31 | Legochem Biosciences, Inc. | Pyrrolobenzodiazepine dimer compound with improved safety and use thereof |
| CA3129868A1 (en) | 2019-03-01 | 2020-09-10 | Mercy Bioanalytics, Inc. | Systems, compositions, and methods for target entity detection |
| US20220226496A1 (en) | 2019-05-02 | 2022-07-21 | Legochem Biosciences, Inc. | Ligand-drug conjugate including linker having tris structure |
| CN114630838A (zh) | 2019-05-20 | 2022-06-14 | 法国国家健康和医学研究院 | 新的抗cd25抗体 |
| US20200370013A1 (en) | 2019-05-20 | 2020-11-26 | The Trustees Of The University Of Pennsylvania | Engineered Expression of Cell Surface and Secreted Sialidase by CAR T Cells for Increased Efficacy in Solid Tumors |
| AR119393A1 (es) | 2019-07-15 | 2021-12-15 | Hoffmann La Roche | Anticuerpos que se unen a nkg2d |
| BR112022013008A2 (pt) | 2019-12-31 | 2022-09-06 | Legochem Biosciences Inc | Composto derivado de pirrolobenzodiazepina, conjugado de derivado-ligante de pirrolobenzodiazepina, e, composição farmacêutica e método para prevenção ou tratamento de doença proliferativa |
-
2022
- 2022-08-04 JP JP2024506691A patent/JP2024531915A/ja active Pending
- 2022-08-04 US US18/294,677 patent/US20250101126A1/en active Pending
- 2022-08-04 EP EP22764488.7A patent/EP4380604A1/en active Pending
- 2022-08-04 AU AU2022324456A patent/AU2022324456A1/en active Pending
- 2022-08-04 KR KR1020247007068A patent/KR20240107093A/ko active Pending
- 2022-08-04 CA CA3228178A patent/CA3228178A1/en active Pending
- 2022-08-04 WO PCT/US2022/039390 patent/WO2023014863A1/en not_active Ceased
- 2022-08-05 TW TW111129544A patent/TW202325726A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202325726A (zh) | 2023-07-01 |
| AU2022324456A1 (en) | 2024-02-15 |
| WO2023014863A1 (en) | 2023-02-09 |
| KR20240107093A (ko) | 2024-07-08 |
| JP2024531915A (ja) | 2024-09-03 |
| EP4380604A1 (en) | 2024-06-12 |
| US20250101126A1 (en) | 2025-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7859981B2 (ja) | 抗グリコcd44抗体およびその使用 | |
| US20250304716A1 (en) | Anti-glyco-muc1 antibodies and their uses | |
| CA3078812A1 (en) | Anti-glyco-muc1 antibodies and their uses | |
| US20250066498A1 (en) | Anti-glyco-lamp1 antibodies and their uses | |
| US20250136701A1 (en) | Anti-glyco-cmet antibodies and their uses | |
| US20250101126A1 (en) | Anti-glyco-muc4 antibodies and their uses | |
| US20250326855A1 (en) | Anti-glyco-cd44 antibodies and their uses | |
| HK40114974A (en) | Anti-glyco-muc4 antibodies and their uses | |
| CN118354788A (zh) | 抗糖-muc4抗体及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240726 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240726 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250728 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250728 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260731 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260731 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260804 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260804 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260804 |